Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Down 14.6% in February

Iterum Therapeutics plc (NASDAQ:ITRM - Get Free Report) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 1,580,000 shares, a decrease of 14.6% from the February 13th total of 1,850,000 shares. Currently, 4.7% of the company's shares are sold short. Based on an average daily volume of 783,000 shares, the days-to-cover ratio is currently 2.0 days.

Institutional Trading of Iterum Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Lee Financial Co acquired a new position in shares of Iterum Therapeutics during the fourth quarter worth about $28,000. Sanctuary Advisors LLC purchased a new stake in shares of Iterum Therapeutics during the 4th quarter valued at about $35,000. XTX Topco Ltd acquired a new position in Iterum Therapeutics during the 3rd quarter worth approximately $36,000. Citadel Advisors LLC acquired a new position in Iterum Therapeutics during the 4th quarter worth approximately $38,000. Finally, Two Sigma Investments LP acquired a new stake in Iterum Therapeutics in the fourth quarter valued at approximately $45,000. 9.21% of the stock is currently owned by institutional investors and hedge funds.

Iterum Therapeutics Price Performance

NASDAQ ITRM traded down $0.01 during mid-day trading on Friday, hitting $1.44. The company's stock had a trading volume of 280,262 shares, compared to its average volume of 967,265. The stock's fifty day simple moving average is $1.46 and its two-hundred day simple moving average is $1.48. Iterum Therapeutics has a 52-week low of $0.81 and a 52-week high of $3.02. The firm has a market capitalization of $49.80 million, a P/E ratio of -1.10 and a beta of 2.44.

Remove Ads

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.